Drug Delivery
Total Trials
15
As Lead Sponsor
8
As Collaborator
7
Total Enrollment
1,439
NCT02081300
Safety and Efficacy of Oral LPCN 1021 in Men With Low Testosterone or Hypogonadism
Phase: Phase 3
Role: Lead Sponsor
Start: Feb 28, 2014
Completion: May 31, 2015
NCT03242590
Dosing Validation Study of Oral Testosterone Undecanoate (TU, LPCN 1021).
Start: Dec 31, 2016
Completion: Jul 31, 2017
NCT03242408
Dosing Flexibility Study of Oral Testosterone Undecanoate (TU, LPCN 1021)
Start: Jan 31, 2017
NCT03868059
Ambulatory Blood Pressure Monitoring in Oral Testosterone Undecanoate (TU, LPCN 1021) Treated Hypogonadal Men
Start: Apr 30, 2018
Completion: Feb 21, 2019
NCT04134091
The Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitis
Phase: Phase 2
Start: Aug 27, 2019
Completion: Jun 24, 2021
NCT04685993
A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial
Start: Nov 11, 2020
Completion: Mar 1, 2022
NCT04874350
A Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and Sarcopenia
Start: Nov 30, 2021
Completion: Dec 18, 2023
NCT06979544
A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD
Start: Jun 16, 2025
Completion: May 31, 2026
Loading map...